For HER2-mutant NSCLC, the combination treatments exhibited an ORR of 46.7% and a median PFS of 8.1 months, comparable to current HER2 ADCs like T-DXd and T-DM1 (19, 21). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.